{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:16Z","timestamp":1791260176733,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In this study, the authors aimed to compare the pharmacokinetics (PK) of micafungin in critically ill patients receiving continuous venovenous hemofiltration (CVVH, 30 mL\u00b7kg<jats:sup>\u22121<\/jats:sup>\u00b7h<jats:sup>\u22121<\/jats:sup>) with those of patients receiving equidoses of hemodiafiltration (CVVHDF, 15 mL\u00b7kg<jats:sup>\u22121<\/jats:sup>\u00b7h<jats:sup>\u22121<\/jats:sup> + 15 mL\u00b7kg<jats:sup>\u22121<\/jats:sup>\u00b7h<jats:sup>\u22121<\/jats:sup>) and determine the optimal dosing regimen using the developed model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with septic shock undergoing continuous renal replacement therapy and receiving a conventional dose of 100 mg micafungin once daily were eligible for inclusion. Total micafungin plasma concentrations from 8 CVVH sessions and 8 CVVHDF sessions were subjected to a population PK analysis using Pmetrics. Validation of the model performance was reinforced by external validation. Monte Carlo simulations were performed considering the total ratio of free drug area under the curve (AUC) over 24 hours to the minimum inhibitory concentration (MIC) (AUC<jats:sub>0-24<\/jats:sub>\/MIC) in plasma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The median total body weight (min\u2013max) was 94.8 (66\u2013138) kg. Micafungin concentrations were best described by a 2-compartmental PK model. No covariates, including continuous renal replacement therapy modality (CVVH or CVVHDF), were retained in the final model. The mean parameter estimates (SD) were 0.96 (0.32) L\/h for clearance and 14.8 (5.3) L for the central compartment volume. External validation confirmed the performance of the developed PK model. Dosing simulations did not support the use of standard 100 mg daily dosing, except for <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic> on the second day of therapy. A loading dose of 150 mg followed by 100 mg daily reached the probability of target attainment for all <jats:italic toggle=\"yes\">C. albicans<\/jats:italic> and <jats:italic toggle=\"yes\">C. glabrata,<\/jats:italic> but not for <jats:italic toggle=\"yes\">C. krusei<\/jats:italic> and <jats:italic toggle=\"yes\">C. parapsilosis<\/jats:italic>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>No difference was observed in micafungin PK between equidoses of CVVH and CVVHDF. A loading dose of 150 mg is required to achieve the PK\/PD target for less susceptible <jats:italic toggle=\"yes\">Candida<\/jats:italic> species from the first day of therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000874","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T20:49:41Z","timestamp":1613940581000},"page":"747-755","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis"],"prefix":"10.1097","volume":"43","author":[{"given":"Nicolas","family":"Garbez","sequence":"first","affiliation":[{"name":"Service des R\u00e9animations, P\u00f4le Anesth\u00e9sie R\u00e9animation Douleur Urgence, Centre Hospitalier Universitaire (CHU) N\u00eemes, N\u00eemes ;"},{"name":"Laboratoire de Pharmacocin\u00e9tique, Facult\u00e9 de Pharmacie, Univ Montpellier ;"},{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litaty C.","family":"Mbatchi","sequence":"additional","affiliation":[{"name":"Laboratoire de Pharmacocin\u00e9tique, Facult\u00e9 de Pharmacie, Univ Montpellier ;"},{"name":"Laboratoire de Biochimie, CHU N\u00eemes, H\u00f4pital Car\u00e9meau, N\u00eemes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Maseda","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Surgical Intensive Care, Hospital Universitario La Paz, ;"},{"name":"Departamento de Cirug\u00eda, Universidad Aut\u00f3noma de Madrid, Madrid ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d Investigacions M\u00e9diques (IMIM), Universitat Aut\u00f3noma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Grau","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain;"},{"name":"Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d Investigacions M\u00e9diques (IMIM), Universitat Aut\u00f3noma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[{"name":"UQ Centre for Clinical Research, the University of Queensland ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Muller","sequence":"additional","affiliation":[{"name":"Service des R\u00e9animations, P\u00f4le Anesth\u00e9sie R\u00e9animation Douleur Urgence, Centre Hospitalier Universitaire (CHU) N\u00eemes, N\u00eemes ;"},{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"},{"name":"UQ Centre for Clinical Research, the University of Queensland ;"},{"name":"Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"},{"name":"UQ Centre for Clinical Research, the University of Queensland ;"},{"name":"Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital ;"},{"name":"Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, the University of Queensland ; and"},{"name":"Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Lefrant","sequence":"additional","affiliation":[{"name":"Service des R\u00e9animations, P\u00f4le Anesth\u00e9sie R\u00e9animation Douleur Urgence, Centre Hospitalier Universitaire (CHU) N\u00eemes, N\u00eemes ;"},{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Roger","sequence":"additional","affiliation":[{"name":"Service des R\u00e9animations, P\u00f4le Anesth\u00e9sie R\u00e9animation Douleur Urgence, Centre Hospitalier Universitaire (CHU) N\u00eemes, N\u00eemes ;"},{"name":"Equipe d'accueil 2992 Caract\u00e9ristiques F\u00e9minines des Interfaces Vasculaires (IMAGINE), Facult\u00e9 de m\u00e9decine, Univ Montpellier, Montpellier ;"},{"name":"Pharmacy Department, Hospital del Mar, Infectious Pathology and Antimicrobial Research Group (IPAR), Institut Hospital del Mar d Investigacions M\u00e9diques (IMIM), Universitat Aut\u00f3noma de Barcelona (UAB), CEXS-Universitat Pompeu Fabra, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","article-title":"Sepsis in European intensive care units: results of the SOAP study","volume":"34","author":"Vincent","year":"2006","journal-title":"Crit Care Med."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","article-title":"Continuous renal replacement therapy: a worldwide practice survey: the beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators","volume":"33","author":"Uchino","year":"2007","journal-title":"Intensive Care Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","article-title":"Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review","volume":"39","author":"Sinnollareddy","year":"2012","journal-title":"Int J Antimicrob Agents."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1007\/s00134-012-2695-9","article-title":"Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT international cohort study","volume":"38","author":"Tabah","year":"2012","journal-title":"Intensive Care Med."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13054-016-1229-1","article-title":"Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study","volume":"20","author":"Paiva","year":"2016","journal-title":"Crit Care"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/JCM.00566-08","article-title":"Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1086\/599039","article-title":"Epidemiology and outcomes of Candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry","volume":"48","author":"Horn","year":"2009","journal-title":"Clin Infect Dis."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"e0127534","DOI":"10.1371\/journal.pone.0127534","article-title":"Clinical and therapeutic aspects of candidemia: a five year single centre study","volume":"10","author":"Bassetti","year":"2015","journal-title":"PLoS One"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","article-title":"Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study","volume":"40","author":"Roberts","year":"2012","journal-title":"Crit Care Med."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.accpm.2018.10.006","article-title":"Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics","volume":"37","author":"Jamal","year":"2018","journal-title":"Anaesth Crit Care Pain Med."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) Patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12882-017-0564-z","article-title":"The impact of continuous renal replacement therapy on renal outcomes in dialysis-requiring acute kidney injury may be related to the baseline kidney function","volume":"18","author":"de Souza Oliveira","year":"2017","journal-title":"BMC Nephrol."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1159\/000441579","article-title":"Application of continuous renal replacement therapy: what should we consider based on existing evidence?","volume":"40","author":"Hanafusa","year":"2015","journal-title":"Blood Purif."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/cc11458","article-title":"Hemofiltration compared to hemodialysis for acute kidney injury: systematic review and meta-analysis","volume":"16","author":"Friedrich","year":"2012","journal-title":"Crit Care"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000321488","article-title":"Principles of antibacterial dosing in continuous renal replacement therapy","volume":"30","author":"Choi","year":"2010","journal-title":"Blood Purif."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","article-title":"Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy","volume":"46","author":"Pea","year":"2007","journal-title":"Clin Pharmacokinet."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03261928","article-title":"Fundamentals of population pharmacokinetic modelling: modelling and software","volume":"51","author":"Kiang","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.accpm.2018.10.013","article-title":"French legal approach to clinical research","volume":"37","author":"Toulouse","year":"2018","journal-title":"Anaesth Crit Care Pain Med."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA score to assess the incidence of organ dysfunction\/failure in intensive care units: results of a multicenter, prospective study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit Care Med."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","article-title":"Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R","volume":"34","author":"Neely","year":"2012","journal-title":"Ther Drug Monit."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10928-013-9302-8","article-title":"Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian","volume":"40","author":"Tatarinova","year":"2013","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jac\/dku013","article-title":"Micafungin pharmacokinetic\/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration","volume":"69","author":"Maseda","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1128\/AAC.00623-15","article-title":"Altered micafungin pharmacokinetics in intensive care unit patients","volume":"59","author":"Lempers","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","article-title":"Population pharmacokinetic model and pharmacokinetic target attainment of micafungin in intensive care unit patients","volume":"56","author":"Martial","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1128\/AAC.00727-16","article-title":"Comparative population plasma and tissue pharmacokinetics of micafungin in critically ill patients with severe burn injuries and patients with complicated intra-abdominal infection","volume":"60","author":"Garc\u00eda-de-Lorenzo","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.diagmicrobio.2007.09.018","article-title":"Population pharmacokinetics of micafungin in adult patients","volume":"60","author":"Gumbo","year":"2008","journal-title":"Diagn Microbiol Infect Dis."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1093\/jac\/dkv173","article-title":"Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis","volume":"70","author":"Grau","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jac\/dkw352","article-title":"Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation","volume":"72","author":"Jullien","year":"2017","journal-title":"J Antimicrob Chemother."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02425-16","article-title":"Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients","volume":"61","author":"Vossen","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"e01398","DOI":"10.1128\/AAC.01398-17","article-title":"Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis","volume":"61","author":"Boonstra","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/viru.26187","article-title":"Invasive candidiasis as a cause of sepsis in the critically ill patient","volume":"5","author":"Delaloye","year":"2014","journal-title":"Virulence"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13054-018-2068-z","article-title":"Are we near to the end of the standard dose of micafungin?","volume":"22","author":"Agrifoglio","year":"2018","journal-title":"Crit Care"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12281-018-0305-1","article-title":"Antifungal dosing considerations in patients undergoing continuous renal replacement therapy","volume":"12","author":"Roger","year":"2018","journal-title":"Curr Fungal Infect Rep."}],"updated-by":[{"DOI":"10.1097\/ftd.0000000000000954","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000}}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:10:07Z","timestamp":1748970607000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000874"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000874","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2020-11-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}